Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bone Biologics CorpBBLG · Entity 8560 | Chief Financial Officer | January 08, 2026 | January 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bone Biologics Corp
Report date January 08, 2026 · Filed January 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.55 · Expires 2036-01-08 | Direct | 8,335 |
Reported balance
After 2026-01-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-08 · Grant · Acquired 8,335 · Balance 8,335 F1: This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests and becomes exercisable immediately. |
| Employee Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $5.82 · Expires 2027-01-15 | Direct | 4,510 |
Reported balance
Holding disclosure · report date 2026-01-08 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 4,510 F2: This option is fully vested as of the date of this report. |
| Common StockSEC Table I · non-derivative | Direct | 313 |
Reported balance
Holding disclosure · report date 2026-01-08 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 313 |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests and becomes exercisable immediately.
F2: This option is fully vested as of the date of this report.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 08, 2026 Filed Jan 21, 2026 16:37 UTC | Bone Biologics Corp BBLG · Entity 8560 | GrantEmployee Stock Option · Derivative | 8,335 | $0.00 Strike: $1.55 | $0.00 |
DisclosureSEC source: 0001493152-26-003103 · ownership.xml · derivative · entry 2 Walsh Deina H · CIK 0001651572 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,335 Underlying: Common Stock · 8,335 shares Expires 2036-01-08 F1 · derivative.underlying_shares: This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests and becomes exercisable immediately. Read SEC document |
| January 15, 2025 Filed Jan 21, 2025 06:06 UTC | Bone Biologics Corp BBLG · Entity 8560 | GrantEmployee Stock Option · Derivative | 27,055 | $0.00 Strike: $0.97 | $0.00 |
DisclosureSEC source: 0001493152-25-002880 · ownership.xml · derivative · entry 2 Walsh Deina H · CIK 0001651572 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,055 Underlying: Common Stock · 27,055 shares Expires 2027-01-15 F1 · derivative.underlying_shares: This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests and becomes exercisable immediately. Read SEC document |
| January 17, 2024 Filed Jan 19, 2024 17:24 UTC | Bone Biologics Corp BBLG · Entity 8560 | GrantEmployee Stock Option · Derivative | 12,500 | $0.00 Strike: $3.61 | $0.00 |
DisclosureSEC source: 0001493152-24-003099 · ownership.xml · derivative · entry 2 Walsh Deina H · CIK 0001651572 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2026-01-17 F1 · derivative.underlying_shares: This option was granted under the Bone Biologics Corporation 2015 Equity Incentive Plan, in a transaction exempt under Rule 16b-3 and, except as otherwise provided in the award notice, vests and becomes exercisable immediately. Read SEC document |
| September 13, 2023 Filed Sep 14, 2023 11:08 UTC | Bone Biologics Corp BBLG · Entity 8560 | PurchaseCommon Stock | 8,000 | $0.64 | $5,120.00 |
DisclosureSEC source: 0001493152-23-032583 · ownership.xml · nonDerivative · entry 1 Walsh Deina H · CIK 0001651572 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Read SEC document |
| September 06, 2023 Filed Sep 7, 2023 10:45 UTC | Bone Biologics Corp BBLG · Entity 8560 | PurchaseCommon Stock | 6,700 | $0.71 | $4,757.00 |
DisclosureSEC source: 0001493152-23-031935 · ownership.xml · nonDerivative · entry 2 Walsh Deina H · CIK 0001651572 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,000 Read SEC document |
| September 06, 2023 Filed Sep 7, 2023 10:45 UTC | Bone Biologics Corp BBLG · Entity 8560 | PurchaseCommon Stock | 300 | $0.70 | $210.00 |
DisclosureSEC source: 0001493152-23-031935 · ownership.xml · nonDerivative · entry 1 Walsh Deina H · CIK 0001651572 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300 Read SEC document |
| January 25, 2023 Filed Mar 8, 2023 06:20 UTC | Bone Biologics Corp BBLG · Entity 8560 | GrantEmployee Stock Option · Derivative | 18,875 | $0.00 Strike: $0.24 | $0.00 |
DisclosureSEC source: 0001493152-23-006965 · ownership.xml · derivative · entry 1 Walsh Deina H · CIK 0001651572 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,875 Underlying: Common Stock · 18,875 shares Expires 2025-01-25 Read SEC document |
| January 03, 2022 Filed Feb 28, 2022 06:04 UTC | Bone Biologics Corp BBLG · Entity 8560 | GrantEmployee Stock Option · Derivative | 25,000 | $0.00 Strike: $3.72 | $0.00 |
DisclosureSEC source: 0001493152-22-005547 · ownership.xml · derivative · entry 1 Walsh Deina H · CIK 0001651572 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2025-01-03 Read SEC document |
| February 16, 2018 Filed Mar 20, 2018 16:14 UTC | Bone Biologics Corp BBLG · Entity 8560 | GrantRestricted Stock Unit · Derivative | 28,426 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001493152-18-003653 · form4.xml · derivative · entry 1 Walsh Deina H · CIK 0001651572 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,530 Underlying: Common Stock · 28,426 shares Expires not disclosed F1 · derivative.exercise_date: On February 16, 2018, the Reporting Person was granted 28,426 shares of restricted stock units which will become fully vested 2 years from the grant date on February 16, 2020, provided the Reporting Person is still providing services to the issuer on the respective date. F1 · derivative.expiration_date: On February 16, 2018, the Reporting Person was granted 28,426 shares of restricted stock units which will become fully vested 2 years from the grant date on February 16, 2020, provided the Reporting Person is still providing services to the issuer on the respective date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.